Are we too passive in our attempts to prevent respiratory syncytial virus infection in Northern Canada?(2014).
Bronchiectasis in children from qikiqtani (baffin) region, nunavut, Canada. (2015).
Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants. (2009).
The real-life effectiveness of palivizumab for re-ducing hospital admissions for respiratory syncytial virus in infants residing in Nunavut.(2014).
Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus. (2013).
Antibiotics for bronchiolitis in children under two years of age. (2014).
Clinical Presentation and Birth Outcomes Associated with Respiratory Syncytial Virus Infection in Pregnancy. (2016).
Global RSV surveillance. (2016).
More on Viral Bronchiolitis in Children. (2016).
Recent advances in the development of subunit-based RSV vaccines. (2016).
Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: Systematic review and meta-analysis. (2015).
Social, economic, and health impact of the respiratory syncytial virus: a systematic search. (2014).
Systematic literature review assessing tobacco smoke ex-posure as a risk factor for serious respiratory syncytial virus disease among infants and young children. (2012).
Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis.(2016).
Where are we with RSV prophylaxis? (2016).